Mangalam Drugs & Organics Limited (MANGALAM.NS)
INR 77.69
(4.13%)
INR 77.69
(4.13%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.67 Billion INR | -0.43% |
| 2022 | 3.7 Billion INR | -17.25% |
| 2021 | 4.47 Billion INR | 17.75% |
| 2020 | 3.79 Billion INR | 34.63% |
| 2019 | 2.82 Billion INR | 26.02% |
| 2018 | 2.23 Billion INR | -18.83% |
| 2017 | 2.75 Billion INR | -8.91% |
| 2016 | 3.02 Billion INR | 2.67% |
| 2015 | 2.95 Billion INR | 33.75% |
| 2014 | 2.2 Billion INR | 80.33% |
| 2013 | 1.22 Billion INR | -2.35% |
| 2012 | 1.25 Billion INR | -18.23% |
| 2011 | 1.53 Billion INR | 16.62% |
| 2010 | 1.31 Billion INR | 16.98% |
| 2009 | 1.12 Billion INR | 9.66% |
| 2008 | 1.02 Billion INR | 7.79% |
| 2007 | 949.99 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 765.36 Million INR | -25.14% |
| 2023 Q2 | 813.66 Million INR | -6.48% |
| 2023 Q1 | 870.03 Million INR | -7.48% |
| 2023 FY | 3.68 Billion INR | -0.43% |
| 2023 Q4 | 1.02 Billion INR | 5.35% |
| 2023 Q3 | 970.45 Million INR | 19.27% |
| 2022 Q3 | 620.87 Million INR | -41.63% |
| 2022 Q4 | 940.39 Million INR | 51.46% |
| 2022 FY | 3.7 Billion INR | -17.25% |
| 2022 Q1 | 1.07 Billion INR | -19.96% |
| 2022 Q2 | 1.06 Billion INR | -1.24% |
| 2021 Q3 | 938.36 Million INR | -17.83% |
| 2021 Q2 | 1.14 Billion INR | 8.99% |
| 2021 Q1 | 1.04 Billion INR | 15.68% |
| 2021 Q4 | 1.34 Billion INR | 43.39% |
| 2021 FY | 4.47 Billion INR | 17.75% |
| 2020 Q2 | 970.25 Million INR | -6.38% |
| 2020 FY | 3.79 Billion INR | 34.63% |
| 2020 Q1 | 1.03 Billion INR | 17.84% |
| 2020 Q4 | 905.74 Million INR | 2.13% |
| 2020 Q3 | 886.87 Million INR | -8.59% |
| 2019 Q4 | 879.52 Million INR | 41.99% |
| 2019 FY | 2.82 Billion INR | 26.02% |
| 2019 Q1 | 650.42 Million INR | 46.3% |
| 2019 Q2 | 672.73 Million INR | 3.43% |
| 2019 Q3 | 619.43 Million INR | -7.92% |
| 2018 Q1 | 590.07 Million INR | -12.19% |
| 2018 FY | 2.23 Billion INR | -18.83% |
| 2018 Q4 | 444.57 Million INR | -8.49% |
| 2018 Q3 | 485.82 Million INR | -32.43% |
| 2018 Q2 | 719 Million INR | 21.85% |
| 2017 Q2 | 831.41 Million INR | 50.79% |
| 2017 FY | 2.75 Billion INR | -8.91% |
| 2017 Q4 | 671.95 Million INR | -9.08% |
| 2017 Q1 | 551.36 Million INR | -33.5% |
| 2017 Q3 | 739.07 Million INR | -11.11% |
| 2016 Q2 | 764.31 Million INR | 14.12% |
| 2016 FY | 3.02 Billion INR | 2.67% |
| 2016 Q4 | 829.09 Million INR | 7.81% |
| 2016 Q3 | 769 Million INR | 0.61% |
| 2016 Q1 | 669.72 Million INR | -5.07% |
| 2015 FY | 2.95 Billion INR | 33.75% |
| 2015 Q1 | 695.6 Million INR | -13.47% |
| 2015 Q2 | 725.56 Million INR | 4.31% |
| 2015 Q3 | 823.54 Million INR | 13.5% |
| 2015 Q4 | 705.5 Million INR | -14.33% |
| 2014 Q3 | 607.83 Million INR | 48.8% |
| 2014 Q4 | 803.93 Million INR | 32.26% |
| 2014 Q2 | 408.49 Million INR | 5.94% |
| 2014 Q1 | 385.58 Million INR | 2.07% |
| 2014 FY | 2.2 Billion INR | 80.33% |
| 2013 Q1 | 183.54 Million INR | -60.02% |
| 2013 FY | 1.22 Billion INR | -2.35% |
| 2013 Q4 | 377.74 Million INR | -0.76% |
| 2013 Q3 | 380.63 Million INR | 35.33% |
| 2013 Q2 | 281.26 Million INR | 53.24% |
| 2012 Q3 | 354.87 Million INR | 76.5% |
| 2012 Q2 | 201.06 Million INR | -15.37% |
| 2012 Q1 | 237.59 Million INR | -42.8% |
| 2012 FY | 1.25 Billion INR | -18.23% |
| 2012 Q4 | 459.05 Million INR | 29.36% |
| 2011 FY | 1.53 Billion INR | 16.62% |
| 2011 Q3 | 377.65 Million INR | 0.0% |
| 2011 Q4 | 415.37 Million INR | 9.99% |
| 2010 FY | 1.31 Billion INR | 16.98% |
| 2009 FY | 1.12 Billion INR | 9.66% |
| 2008 FY | 1.02 Billion INR | 7.79% |
| 2007 FY | 949.99 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 93.99% |
| Hester Biosciences Limited | 3.04 Billion INR | -20.623% |
| Aarti Drugs Limited | 25.28 Billion INR | 85.472% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 79.766% |
| Albert David Limited | 3.62 Billion INR | -1.35% |
| Alembic Limited | 1.57 Billion INR | -133.262% |
| Alkem Laboratories Limited | 126.67 Billion INR | 97.1% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -140.942% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 22.404% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -817.574% |
| Brooks Laboratories Limited | 794.86 Million INR | -362.161% |
| Eris Lifesciences Limited | 20.09 Billion INR | 81.716% |
| FDC Limited | 19.42 Billion INR | 81.093% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 83.911% |
| Gufic Biosciences Limited | 8.06 Billion INR | 54.46% |
| Hikal Limited | 17.84 Billion INR | 79.415% |
| Ind-Swift Limited | 5.02 Billion INR | 26.89% |
| Innova Captab Limited | 10.81 Billion INR | 66.027% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 82.776% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -76.018% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 94.519% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 36.723% |
| Lupin Limited | 196.56 Billion INR | 98.131% |
| Medico Remedies Limited | 1.44 Billion INR | -153.486% |
| Morepen Laboratories Limited | 17.01 Billion INR | 78.415% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 78.193% |
| Orchid Pharma Limited | 8.19 Billion INR | 55.166% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 68.091% |
| RPG Life Sciences Limited | 5.82 Billion INR | 36.886% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -137.966% |
| Sigachi Industries Limited | 3.98 Billion INR | 7.921% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 70.336% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 65.059% |
| Themis Medicare Limited | 3.81 Billion INR | 3.774% |
| Unichem Laboratories Limited | 16.57 Billion INR | 77.836% |
| Vaishali Pharma Limited | 862.79 Million INR | -325.771% |
| Wanbury Limited | 5.75 Billion INR | 36.185% |
| Windlas Biotech Limited | 6.3 Billion INR | 41.778% |
| ZIM Laboratories Limited | 3.67 Billion INR | 0.044% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 71.321% |
| Ipca Laboratories Limited | 77.05 Billion INR | 95.233% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.243% |
| Venus Remedies Limited | 5.91 Billion INR | 37.889% |
| Sakar Healthcare Limited | 1.54 Billion INR | -138.282% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 98.733% |
| Divi's Laboratories Limited | 78.45 Billion INR | 95.317% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 71.645% |
| Mankind Pharma Limited | 103.34 Billion INR | 96.445% |
| Sequent Scientific Limited | 13.69 Billion INR | 73.181% |
| Laurus Labs Limited | 50.01 Billion INR | 92.656% |
| Neuland Laboratories Limited | 15.58 Billion INR | 76.43% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 89.345% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 96.89% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 98.069% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 12.79% |
| Wockhardt Limited | 27.89 Billion INR | 86.828% |
| Bal Pharma Limited | 3.39 Billion INR | -8.294% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.684% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 52.307% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -284.099% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 78.092% |
| Shilpa Medicare Limited | 11.53 Billion INR | 68.142% |
| Valiant Laboratories Limited | 1.82 Billion INR | -101.779% |
| Ajanta Pharma Limited | 42.08 Billion INR | 91.272% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 7.144% |
| Granules India Limited | 45.06 Billion INR | 91.848% |
| Medicamen Biotech Limited | 1.79 Billion INR | -104.875% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -41.702% |
| Piramal Enterprises Limited | 60.33 Billion INR | 93.912% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 96.536% |
| NATCO Pharma Limited | 40.02 Billion INR | 90.821% |
| Suven Life Sciences Limited | 116.92 Million INR | -3041.681% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -628.565% |
| Strides Pharma Science Limited | 40.51 Billion INR | 90.932% |
| Indoco Remedies Limited | 18.17 Billion INR | 79.786% |
| Alpa Laboratories Limited | 1.08 Billion INR | -237.831% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -252.09% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -386.269% |